Non-antibiotic modulation of small intestinal dysbiosis with oral simethicone as a treatment for patients with disorders of gut-brain interaction: a randomised placebo-controlled trial

Start Date22 Oct 2025

Sponsor / Collaborator-

NCT07245095

/ RecruitingPhase 2IIT

Randomized Controlled Trial to Evaluate the Effect of Premedication With N-acetylcysteine and Simethicone on Mucosal Visibility During Elective Upper Gastrointestinal Endoscopy Using the TUGS Score

The goal of this randomized, double-blind, placebo-controlled clinical trial is to assess whether the combination of N-acetylcysteine and simethicone improves mucosal visibility during upper gastrointestinal endoscopy in adults aged 18 to 99 years of both sexes, including both healthy individuals and those with non-bleeding gastrointestinal symptoms.
The main questions this study aims to answer are:
Does pre-endoscopy administration of N-acetylcysteine/simethicone improve mucosal visualization based on the Toronto Upper Gastrointestinal Cleanliness Score (TUGS)?
Is this combination safe and well tolerated in this patient population?
Researchers will compare patients receiving N-acetylcysteine (600 mg) and simethicone (100 mg) orally 20-60 minutes before the procedure with those receiving placebo (water) to determine if there is a significant improvement in TUGS scores.
Participants will:
Receive a single oral dose of either N-acetylcysteine/simethicone or placebo prior to endoscopy
Undergo a routine upper GI endoscopy
Have mucosal cleanliness evaluated using the TUGS scoring system
Be monitored for any adverse events or intolerance

Start Date12 Sep 2025

Sponsor / Collaborator-

ChiCTR2500108998

/ RecruitingEarly Phase 1IIT

Feasibility and Accuracy Analysis of AI-Assisted Gastric Volume Assessment

Start Date05 Sep 2025

Sponsor / Collaborator

Sichuan Provincial People's Hospital

100 Clinical Results associated with Simethicone

100 Translational Medicine associated with Simethicone

100 Patents (Medical) associated with Simethicone

318

Literatures (Medical) associated with Simethicone

28 Nov 2025·MEDICINE

Pre-endoscopy drink of small doses of simethicone and pronase solution improves visualization in upper gastrointestinal endoscopy: Randomised double-blind experiment

Article

Author: Li, Yuan ; Sheng, Jinyi ; Wu, Junmin ; Jiang, Jingping

Background::

Upper gastrointestinal endoscopy (UGE) was the gold standard investigative modality for gastrointestinal diseases. High quality of visualization was essential to high-quality UGE. Our aim was to compare the effect of the small doses of simethicone plus pronase in improving visibility during UGE.

Methods::

Four hundred patients underwent UGE and were divided into 4 groups randomly. All patients took medicine 15 to 30 minutes before the examination. The premedication in the group D was dyclonine. The other 3 groups were administered simethicone (group S), pronase solution (group P) alone, and simethicone plus pronase solution (group P + S). The mucosal visibility score and total mucosal visibility score (TMVS) were recorded. The lower the score, the cleaner the gastric mucosa. Adverse events were also recorded.

Results::

We studied the UGE pictures of 400 patients. The group P + S had a significantly better TMVS than the other groups (4.91 ± 0.99 in group P + S vs 6.76 ± 1.58 in group D, P < .05; 4.91 ± 0.99 in group P + S vs 5.61 ± 0.91 in group S, P < .05; 4.91 ± 0.99 in group P + S vs 6.46 ± 0.82 in group P, P < 0. 05). However, there was no significant differences were found between group D versus group P on TMVS.

Conclusion::

The application of small doses of simethicone and pronase solution can create good mucosal and has no side effects.

27 Nov 2025·Gut and Liver

Efficacy and Safety of Bowel Cleansing with Mini S-Oral Sulfate Tablet versus the Conventional Oral Sulfate Tablet: A Prospective, Randomized, Investigator-Blinded, Multicenter, Noninferior, Phase 3 Trial

Article

Author: Cha, Jae Myung ; Jeon, Seong Ran ; Park, Soo-Kyung ; Yang, Dong-Hoon ; Chun, Jaeyoung

Background/Aims:

Conventional oral sulfate tablets (OSTs) and mini-OSTs have gained popularity for bowel preparation in South Korea. This study aimed to evaluate the efficacy, tolerability, and safety of mini S-OSTs, which have fewer tablets and include simethicone compared to the mini-OSTs.

Methods:

This was a prospective, randomized, investigator-blinded, multicenter, and noninferior phase 3 trial conducted between August 2023 and January 2024. The efficacy, safety, and tolerability were compared among a mini S-OST split dose group, mini S-OST non-split dose group and conventional OST group. To evaluate the occurrence of gastric mucosal lesions, gastroscopy was also performed.

Results:

High-quality preparation was achieved in the mini S-OST split dose group and conventional OST group according to both the full analysis set and per-protocol set analyses, without significant differences. Tolerability metrics were more favorable in the mini-OST group. The hematin content tended to decrease and the number of erosions was reduced in the mini S-OST split dose group compared with the conventional OST group according to the gastroscopy results. Adverse events were comparable between the conventional OST and mini S-OST split dose groups. The mini S-OST non-split dose group showed no difference in overall successful cleaning, but the proportion of high-quality cleaning in the ascending colon was lower than that in the mini S-OST split dose group and conventional OST group.

Conclusions:

Compared with conventional OST, the mini S-OST split dose showed excellent efficacy, comparable safety and tolerability, with less gastric injury (ClinicalTrial.gov identifier NCT06287606).

01 Oct 2025·NEUROGASTROENTEROLOGY AND MOTILITY

Drug Survival of Drugs Recommended for Irritable Bowel Syndrome: A Retrospective Observational Study

Article

Author: Sandberg‐Janzon, Alice ; Karling, Pontus

ABSTRACT:

Background:

There is limited data on how drugs prescribed for functional bowel disorders are re‐prescribed in clinical practice. This study aimed to investigate drug survival rates of different irritable bowel syndrome (IBS) treatments among patients referred to a gastroenterologist.

Methods:

A retrospective observational study was conducted by reviewing medical charts of patients aged 18–50 years, diagnosed with IBS or an unspecified functional intestinal disorder between 2010 and 2018. Drug survival rates for various treatment categories were analyzed using Kaplan–Meier curves and log‐rank tests.

Results:

A total of 1528 treatment attempts were recorded in 529 patients, with 883 classified as treatment‐naïve. Simethicones demonstrated significantly higher drug survival compared to bulking agents (p = 0.009). Tricyclic antidepressants (TCA), loperamide, and simethicones all showed superior survival rates compared to osmotic laxatives (p = 0.039, p = 0.025 and p = 0.003, respectively). Additionally, loperamide and simethicones had better survival rates than antispasmodics (p = 0.046 and p = 0.012, respectively). At 60 months, the cumulative drug survival rate was highest for TCA (11%), followed by loperamide (10%) and simethicones (7%), all significantly outperforming bulking agents (1%) (p = 0.002 for TCA vs. bulking agents, p = 0.002 for loperamide vs. bulking agents, and p = 0.006 for simethicones vs. bulking agents). For all treatment‐naïve attempts, the cumulative drug survival at 60 months was 6%.

Conclusions:

The overall 60‐month drug survival for treatments prescribed in IBS is relatively low, suggesting that the effectiveness of current therapies remains limited. Among the medications studied, simethicone and TCAs demonstrated the best drug survival rates.

News (Medical) associated with Simethicone

06 Mar 2025

·www.drugs.com

Updates Issued for Optimizing Bowel Preparation Quality for Colonoscopy

THURSDAY, March 6, 2025 -- In updated consensus recommendations published online March 4 in the American Journal of Gastroenterology , additional guidance is presented for optimizing bowel preparation quality for colonoscopy . Brian C. Jacobson, M.D., M.P.H., from Massachusetts General Hospital in Boston, and colleagues developed consensus statements and key clinical concepts addressing aspects of bowel preparation for colonoscopy to update the 2014 recommendations for optimizing the adequacy of bowel cleansing. The authors noted that most of the consensus statements focus on individuals at average risk for inadequate bowel preparation; statements are also provided addressing individuals at risk for inadequate bowel preparation quality. Use of a split-dose bowel preparation regimen is recommended; and a 2-liter regimen is suggested as sufficient. For individuals undergoing afternoon colonoscopy, a same-day regimen is recommended as an acceptable alternative; however, for individuals undergoing morning colonoscopy, a same-day regimen is inferior. Dietary restrictions should be limited to the day before a colonoscopy; for early and midday meals, clear liquids or low-fiber/low-residue diets should be relied on. Adjunctive use of oral simethicone is suggested for bowel preparation before colonoscopy. There is also a recommendation for routine tracking of the rate of adequate bowel preparations at the level of individual endoscopists and the endoscopy unit, with a target >90 percent for both rates. "Bowel preparation is a vital part of colonoscopy. If the colon is not adequately cleaned, the person performing the colonoscopy may miss important findings such as small polyps," Jacobson said in a statement. "Many cases end up cancelled when the bowel preparation is inadequate, and that creates tremendous frustration for patients and inefficient use of resources." Several authors disclosed ties to the biopharmaceutical and medical device industries. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

08 Apr 2024

·www.prnewswire.com

Wonderbelly Expands its Suite of Digestive Health Medicines with Launch of Bloat + Gas Relief

AUSTIN, Texas, April 8, 2024 /PRNewswire/ -- Wonderbelly, known for its effective digestive medicine, clean* ingredients and tasty flavors, today announced the launch of its latest product: Wonderbelly Bloat + Gas Relief. The launch marks a considerable milestone in Wonderbelly's goal to become the go-to brand for all things digestive health as the company grows into a second category of digestive medicine. Wonderbelly Bloat + Gas Relief is now available to consumers at Target, on Target.com and Amazon.com. Continue Reading Wonderbelly Expands its Suite of Digestive Health Medicines with Launch of Bloat + Gas Relief Post this Wonderbelly launches Bloat + Gas Relief in two delicious flavors, Strawberry Shortcake and Mango Smoothie. Wonderbelly products offer the same highly effective relief as leading medicine brands with a focus on clean ingredients that are Non-GMO and Clean Label Project Certified. Wonderbelly Bloat + Gas Relief has been expertly formulated to effectively combat symptoms like bloating, gas discomfort, abdominal pressure, and associated fullness. Boasting extra strength with 125mg of Simethicone, the company's new medicine comes in two enticing flavors: Strawberry Shortcake and Mango Smoothie. "From the very beginning, we've been committed to reimagining the digestive health experience so that people can feel good about feeling good. After launching Wonderbelly Antacid last year, we're thrilled to expand into a new digestive category to offer consumers highly effective bloat and gas relief in two delicious flavors we know people will love," says Wonderbelly founder Lucas Kraft. "Ultimately, Bloat + Gas represents a natural progression for Wonderbelly and a direct response to consumer demand for medicine that reflects their modern values. We've worked hard with our retail partners to identify customer needs and are proud to deliver a solution that gives them exactly what they're looking for." Building upon the success of Wonderbelly Antacid, which has rapidly become a consumer favorite with over one thousand five-star reviews, Wonderbelly Bloat + Gas Relief further cements Wonderbelly's role as a trailblazer in the rapidly evolving segment of modern digestive health medicine. "It's great to see Wonderbelly really resonate with consumer demand in the medicine space, particularly with trends towards clean ingredients and more sustainable packaging," says brain-gut expert Emeran Mayer, MD (emeranmayer.com). "I'm excited to continue to support Wonderbelly as they expand their offerings to provide relief for a range of digestive health symptoms." Wonderbelly is committed to using recyclable packaging, with bottles made solely of metal to reduce the use of plastic. Produced by one of the leading OTC manufacturers in the United States, Wonderbelly's products and novel packaging undergo rigorous testing, adhering to the stringent standards set for major pharmaceutical products. Wonderbelly can be found in Target and at retail locations across the country, like Wegmans, Meijer, Kroger, Fred Meyer, Fresh Thyme, Giant Eagle*, Raley's*, Harris Teeter, Central Market, Erewhon, Earth Fare, MOM's Organic. *Wonderbelly defines clean medicine as formulated using pharmaceutical active ingredients with inactive ingredients that are Clean Label Project-Certified, vegan, Non-GMO, and free of artificial dyes, artificial sweeteners, talc, titanium dioxide, parabens, gluten, and dairy. For more information about Wonderbelly, please visit Wonderbelly.com For visual assets, please see Dropbox PR Contact: [email protected] About Wonderbelly Wonderbelly™ is a digestive health medicine company founded by brothers Lucas and Noah Kraft. Wonderbelly makes effective and tasty digestive health medicine free from dyes, artificial sweeteners, talc, titanium dioxide, and genetically modified ingredients. Wonderbelly offers two products, Wonderbelly Antacid™ and Wonderbelly Bloat + Gas Relief™, in an assortment of delicious flavors. The company is committed to using recyclable packaging, including metal bottles and compostable on-the-go pouches, to reduce the use of plastic. SOURCE Wonderbelly

11 May 2021

·www.globenewswire.com

Gastrointestinal Drugs Market Growth Sturdy at 4.9% CAGR to

Pune, India., May 10, 2021 (GLOBE NEWSWIRE) -- Gastrointestinal Drugs Market: Key InsightsAccording to our new research study on “Gastrointestinal Drugs Market to 2027 – Global Analysis and Forecast – by Drug Class, Route of Administration, Application, and Distribution Channel,” the Gastrointestinal Drugs Market Size was valued at US$ 49,043.38 million in 2019 and is projected to reach US$ 71,300.28 million by 2027; it is expected to grow at a CAGR of 4.9% during 2020–2027. The extensive rise in COVID-19 infection fuels growth of the market. However, low awareness associated with gastrointestinal disorders in low-income economies is restricting the market growth. Gastrointestinal Drugs Market: Competition Landscape and Key DevelopmentsSanofi; GlaxoSmithKline plc; Johnson and Johnson Services, Inc.; Bausch Health; AstraZeneca; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Bayer AG; Celltrion Healthcare Co., Ltd.; and Lexicon Pharmaceuticals, Inc. are among the key companies operating in the gastrointestinal drugs market. Leading players are focusing on the expansion and diversification of their market presence and acquisition of new customer base, thereby tapping prevailing business opportunities. In January 2020, AstraZeneca recovered the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting IL23, from Allergan. Brazikumab is currently in a Phase IIb/III program in Crohn’s disease (CD) and a Phase IIb trial in ulcerative colitis (UC). AstraZeneca and Allergan will terminate their existing license agreement and all rights to brazikumab will revert to AstraZeneca. The transaction is expected to complete in the first quarter of 2020. Get Exclusive Sample Pages of Gastrointestinal Drugs Market - COVID-19 Impact and Global Analysis with Strategic Insights at In 2019, North America dominated the global gastrointestinal drugs market. The market growth in the region is attributed to increase in incidence of gastrointestinal diseases due to change in lifestyle, government support for prevention and treatment of gastrointestinal diseases, presence of well-developed healthcare infrastructure, growth of pharmaceutical industry, reimbursement coverage, and industry giants. Moreover, according to the National Health Interview Survey, in 2018, about 14.8 million people in the US were diagnosed with ulcers. Furthermore, the National Ambulatory Medical Care Survey: 2016 reported that around 22.4 million patients visited a physician’s office for digestive diseases, and about 8.3 million emergency department visits were for digestive diseases. Also, US Food and Drug Administration (FDA) approvals in the US are likely to favor the growth of the market. For instance, in May 2020, the US FDA approved Qinlock (ripretinib) tablets as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST). Furthermore, developments by the market players in this industry is likely to favor market growth. Based on drug class, the gastrointestinal drugs market is segmented into acid neutralizers, antidiarrheal and laxatives, anti-inflammatory drugs, antiemetic and antinauseants, biologics, and others. The acid neutralizers segment held the largest share of the market in 2019. Based on route of administration, the gastrointestinal drugs market is segmented into oral and parenteral. The oral segment held larger share of the market in 2019 and is estimated to register higher CAGR in the market during the forecast period. Based on application, the gastrointestinal drugs market is segmented into inflammatory ulcerative colitis, Crohn's disease, irritable bowel syndrome, gastroenteritis, celiac disease, and others. The inflammatory ulcerative colitis segment held the largest share of the market in 2019. Based on distribution channel, the gastrointestinal drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held the largest share of the market in 2019, and it is estimated to register the highest CAGR in the market during the forecast period. Download Sample PDF Brochure of Gastrointestinal Drugs Market Growth Research Report at The COVID-19 outbreak started in December 2019 in Wuhan (China), and it has spread to ~100 countries across the world, with the World Health Organization (WHO) stating it as a public health emergency. The global impacts of COVID-19 are being felt across several markets. Although the healthcare sector had witnessed SARS, H1N1, and other outbreaks in the last few years, the severity of the COVID-19 has made the situation more complicated due to its mode of transmission. North America has been witnessing a growing number of COVID-19 cases since its outbreak. For instance, according to Worldometer, the number of cases increased to 7,679,908 with 215,039 deaths reported in the US as of October 06, 2020. The cases are also increasing in Mexico and Canada. In Mexico, the cases have reached 761,665, with 79,088 deaths. Similarly, in Canada, there are about 168,960 COVID-19 cases, with 9,504 deaths reported so far. Several companies are cutting their clinical trial activities in response to the COVID-19 pandemic. For instance, slashing clinical trial activity will affect the timelines for Eli Lilly's late-phase trials of mirikizumab in gastrointestinal indications. According to their listings on ClinicalTrials.gov., the phase 3 trials for mirikizumab in Crohn’s disease and ulcerative colitis have primary completion dates ranging from September 2020 to late 2023, which can be a confirmed delay. However, in long run, the demand is expected to increase. For instance, according to the estimates reported by Ironwood Pharmaceutical, the demand for prescription drug product LINZESS—indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation—is expected to increase by 11% from the demand in 2019. Therefore, the growing demand for the constipation treatment in North America in long-term period is likely to boost the growth of the gastrointestinal drugs market. Buy Copy of Gastrointestinal Drugs Market Research Study at Gastrointestinal Drugs Market: Segmental OverviewBased on drug class, the gastrointestinal drugs market is segmented into acid neutralizers, antidiarrheal and laxatives, anti-inflammatory drugs, antiemetic and antinauseants, biologics, and others. The acid neutralizers segment held the largest share of the market in 2019. Antacids are over-the-counter (OTC) medications that neutralize stomach acid and help in relieving heartburn, sour stomach, acid indigestion, and stomach upset. They are available as a liquid or chewable tablet. Some antacids also contain simethicone, an ingredient that helps body in relieving gas. Some antacids contain ingredients that can cause diarrhea, such as magnesium, or constipation, such as aluminum. Based on route of administration, the market is segmented into oral and parenteral. The oral segment held larger share of the market in 2019 and is estimated to register higher CAGR in the market during the forecast period. Based on application, the market is segmented into inflammatory ulcerative colitis, Crohn's disease, irritable bowel syndrome, gastroenteritis, celiac disease, and others. The inflammatory ulcerative colitis segment held the largest share of the market in 2019. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held the largest share of the market in 2019 and is estimated to register the highest CAGR in the market during the forecast period. About Us:The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us:If you have any queries about this report or if you would like further information, please contact us: Contact Person: Sameer JoshiE-mail: sales@theinsightpartners.comPhone: +1-646-491-9876 Press Release -

AntibodyAcquisition

100 Deals associated with Simethicone

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Abdomen distended	United States	-	01 Jan 1952
Flatulence	United States	-	01 Jan 1952

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Abdominal Pain	Phase 3	Russia	Abbott Laboratories	27 Nov 2020
Irritable Bowel Syndrome	Phase 3	Russia	Abbott Laboratories	27 Nov 2020
Gastrointestinal Hemorrhage	Phase 1	United States	Mayo Clinic	30 Apr 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06458881 (Pubmed \| Ital J Pediatr)	Phase 2	Colic	41	Tyndallized Bacillus Coagulans and Simethicone mixture	ljlkiglprx(rkacgetaxh) = upisdhygjb ohsjbeblqk (yhphelvuws )	Positive	12 Nov 2025
NCT05951712 (Pubmed \| Indian J Gastroenterol)	Not Applicable	-	800	simethicone (Water)	eudrmjpvso(zihipptqmi) = loslydyfjq vrnnnyetlj (baxurtpvat, 9 - 13)	Positive	01 Oct 2024
				Simethicone	eudrmjpvso(zihipptqmi) = iihafbtiiz vrnnnyetlj (baxurtpvat, 6 - 8)
NCT05175131 (CTgov)	Phase 3	Abdominal Pain \| Irritable Bowel Syndrome	465	Simethicone+Mebeverine (Mebeverine+Simethicone Combination)	vqdvozpewu(ktgybfilbh) = tdkbtxfmee pooysfvwca (tktsiebllj, 3.42) View more	-	03 Jan 2024
				Mebeverine (Mebeverine)	vqdvozpewu(ktgybfilbh) = sneyuycjqh pooysfvwca (tktsiebllj, 3.48) View more
PREMEDICATION WITH SIMETHICONE (UEGW2021)	Not Applicable	-	110	Simethicone 200mg	yojcuwrubf(tdmcevaooo) = queffdhrzh jlpboybujp (ucmnjhvlvg ) View more	Positive	02 Oct 2021
				Placebo	yojcuwrubf(tdmcevaooo) = wghscpdjch jlpboybujp (ucmnjhvlvg ) View more
NCT02334631 (Pubmed \| PLoS One)	Phase 3	-	167	High volume simethicone	poifrdgyli(safhsdtspz) = abmqsjfhed ifarttcnvt (qzsndfpsak ) View more	-	01 Apr 2021
				Standard volume simethicone	poifrdgyli(safhsdtspz) = ylrmsauriz ifarttcnvt (qzsndfpsak ) View more
NCT03119168 (Pubmed \| Gastrointest Endosc)	Phase 4	-	268	Polyethylene glycol plus SIM	ihbsomjszf(ftnaadcsnj) = zegufyhiob qsycplxmgf (sbwgcobcap ) View more	-	01 Jul 2019
				Polyethylene glycol	ihbsomjszf(ftnaadcsnj) = rzirqwcrtg qsycplxmgf (sbwgcobcap ) View more
NCT03119168 (CTgov)	Phase 4	Adenoma	268	Simethicone Solution (Simethicone Solution + Polyethylenglycol)	gpypdkrbfd = sydrevdhww tiiuugwoqn (spvhiwwjes, hzbmpeaamq - ijdgaecqfj) View more	-	05 Jun 2019
				Polyethylenglycol (Polyethylenglycol)	gpypdkrbfd = ngrjcoqogk tiiuugwoqn (spvhiwwjes, sdjefyxolf - vrsxhymuml) View more
Pubmed	Phase 2/3	-	-	simethicone (PEG)	tkxswgxced(qpfcbdetfb) = ykzjxldtwq eigoldttip (vpwjfanvxx ) View more	-	01 Jan 2018
				simethicone (PEG-S)	tkxswgxced(qpfcbdetfb) = nyrkttdnki eigoldttip (vpwjfanvxx ) View more
NCT02217982 (IIT9, CTgov)	Phase 4	Multiple Sclerosis, Relapsing-Remitting	5	DMF (Control Group)	spbdabcfgp(bxrdrbtgid) = crsdrkovtx wgbxwkkkgv (gxjovcqroz, hkrgpqhrqq - lsufvqgahw) View more	-	06 Jan 2017
				Peanut Butter+Simethicone+Loperamide (Treatment Arm)	spbdabcfgp(bxrdrbtgid) = hkgubbtesa wgbxwkkkgv (gxjovcqroz, ombmllnrba - kfzxqfwkgn) View more
NCT01312038 (CTgov)	Phase 2	Functional disorder \| Otitis Media	25	Placebo (Placebo)	rexanbgqvw(bhsaxfjpth) = sghkootybr afonyedvug (fpstmlsoaj, 0.34) View more	-	27 Jun 2016
				Simethicone (Simethicone)	dxhztiiigk(kbwzqbbeql) = vfksxpkncx izijcxfjuq (vzhllaoeqe, eqrbghkmys - ustleqbgcd) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Simethicone

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation